Gillian Cannon has sold XENE and made no open-market buys since Jun 2026

Gillian M. Cannon, Ph.D. is a seasoned biopharmaceutical executive and board director with more than 30 years of experience in the pharmaceutical industry.( She serves as an Independent Director at Xenon Pharmaceuticals Inc., where she joined the board in 2023 and recently reported routine equity awards and option grants as part of her director compensation.( In addition to her role at Xenon, Dr. Cannon is an Independent Director at Corcept Therapeutics Inc., a Director at Affibody AB, a Director at Edinburgh Innovations Ltd., and has served as President of Alyvant, Inc. since 2018.(

Earlier in her career, Dr. Cannon spent over 27 years at Merck, including leadership roles as Global Commercial Head of the Neuroscience franchise and Global Vice President of Commercial Strategy and Operations, before taking on senior commercial positions such as President of North American Operations at UCB, Inc., Senior Vice President of Customer Strategy and Analytics at Otsuka Pharmaceuticals, and Head of Commercial Innovation at Roivant Sciences.( She holds an undergraduate degree from The University of Edinburgh and doctorate degrees from Temple University (Pennsylvania) and its Fox School of Business, reflecting combined scientific and business training that underpins her board and executive work across multiple life sciences companies.(

Written by Perplexity from public sources.